Roche said on Wednesday its experimental oral drug giredestrant reduced the risk of breast cancer recurrence by 30% compared ...

At the San Antonio Breast Cancer Symposium (SABCS), investigators reported final phase I results of an alpha-lactalbumin (aLA ...

Lumpectomy has been the standard of care for low-risk, early-stage breast cancer, but now cryoablation — freezing cancer ...

Pfizer Inc.’s Tukysa, when given as part of the initial treatment for an advanced form of breast cancer, delayed tumor growth ...

Among more than 4,000 patients with hormone receptor (HR)-positive disease, 3-year invasive disease-free survival (IDFS) ...

Breast cancer comes with many variables. A pair of powerful genomic tests can help women and their care teams make ...

Male breast cancer is rare, but studies suggest it's more common — and more lethal — among veterans. Yet the Veterans Administration is making it harder for veterans with breast cancer to get care.

Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor degrader (SERD) to a 30% reduction in the risk of invasive disease ...

Known as Breast Circulating Methylation Assay (BCMA), the new blood test looks for tumour DNA released into the bloodstream ...

Roche Holding shares rose 2.1% Wednesday after the Swiss drugmaker reported positive results from a new study of an ...

Julia Louis-Dreyfus said she felt forced to go public about her stage 2 breast cancer diagnosis in 2017, and sharing the ...

Years after being diagnosed with breast cancer, Julia Louis-Dreyfus is reflecting on her decision to share her health battle ...